Aspira Pathlab Quarterly Results
Aspira Pathlab quarterly results. In Mar 2025, Aspira Pathlab (ASPIRA) reported revenue ₹6 Cr and net profit ₹1 Cr — revenue +50.0% YoY. View Aspira Pathlab 52-week for the annual high/low range and current price position.
ASPIRA Quarterly Results — Revenue, Profit & EPS Highlights
Aspira Pathlab latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit ASPIRA share price.
- Revenue of ₹6 Cr in Mar 2025 (+20.0% vs Jun 2025, +50.0% vs Mar 2024)
- Net Profit of ₹1 Cr in Mar 2025 (+200.0% vs Mar 2024)
- EBITDA of ₹1 Cr in Mar 2025 (+0.0% vs Jun 2025)
- Operating Margin of 16.0% in Mar 2025 (+3.0pp vs Jun 2025)
- Earnings Per Share of ₹0.66 in Mar 2025 (+61.0% vs Jun 2025)
Aspira Pathlab Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ASPIRA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6 | 5 | 6 | 4 | 5 | 20.0% | 50.0% |
| Net Profit (₹ Cr) | 1 | 0 | 1 | -1 | 0 | - | - |
| EBITDA (₹ Cr) | 1 | 1 | 1 | 0 | 0 | - | - |
| EPS (₹) | 0.66 | 0.41 | 0.96 | -0.49 | 0.05 | - | - |
| Operating Margin (%) | 16.0% | 13.0% | 21.0% | -5.0% | 6.0% | - | - |
ASPIRA Share Price Trend — 1-Year Movement Across Quarterly Results
Aspira Pathlab 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore ASPIRA share price charts to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ASPIRA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Aspira Pathlab latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1884.9 | 16,617 | 1,995 | +10.6% | - | 12.0% | 227.1 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11180.5 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4689.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 407.4 |
|
Apollo Hospitals
Sept 2026 |
₹132,281.88 Cr | 9200.0 | 7,673 | 660 | +15.2% | - | 8.6% | 209.9 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2294.6 | 2,219 | 436 | +21.7% | - | 19.6% | 280.9 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores